A screening tool for ovarian and endometrial cancers has been developed by  Dr. John Martignetti and his teams at Danbury’s Rudy L. Ruggles Biomedical Research Institute and the Icahn School of Medicine at Mount Sinai.

“It could change everything,” said Martignetti, who is network director of the Laboratory for Translational Research at the Western Connecticut Health Network’s Ruggles Institute. “Late stage, 80 percent die of (ovarian) cancer. Early stage, 90 percent will live — so you’ve flipped everything.”